Skip to main content

Table 4 Baseline characteristics of participants by survival status in eastern Uganda

From: Treatment success and mortality among adults with tuberculosis in rural eastern Uganda: a retrospective cohort study

Characteristics

Level

Alive

n = 906 (91.8%)

Died

n = 81 (8.2%)

p-value

District

Soroti

418 (46.1)

45 (55.6)

0.027

Kumi

213 (23.5)

15 (18.5)

 

Ngora

125 (13.8)

16 (19.8)

 

Serere

150 (16.6)

5 (6.2)

 

Level of health facility

Health Center IV

386 (42.6)

22 (27.2)

0.023

District Hospital

182 (20.1)

19 (23.5)

 

Referral Hospital

338 (37.3)

40 (49.4)

 

Location of health facility

Rural

252 (27.8)

23 (28.4)

1.000

Peri-urban

654 (72.2)

58 (71.6)

 

Health facility ownership

Public

808 (89.2)

72 (88.9)

1.000

Private not for profit

98 (10.8)

9 (11.1)

 

Year of TB treatment

2015

332 (36.6)

35 (43.2)

0.022

2016

192 (21.2)

25 (30.9)

 

2017

209 (23.1)

14 (17.3)

 

2018

173 (19.1)

7 (8.6)

 

Age category (years)

15–34

436 (48.1)

24 (29.6)

0.002

35–50

297 (32.8)

31 (38.3)

 

> 50

173 (19.1)

26 (32.1)

 

Mean (SD)

37.95 (15.05)

44.80 (16.82)

< 0.001

Sex

Male

593 (65.5)

58 (71.6)

0.319

Female

313 (34.5)

23 (28.4)

 

Persons with BC-PTB

New

792 (87.4)

70 (86.4)

0.933

Previously treated

114 (12.6)

11 (13.6)

 

Transfer in

No

830 (91.6)

73 (90.1)

0.801

Yes

76 (8.4)

8 (9.9)

 

Pre-therapy MTB load

1+

130 (14.3)

12 (14.8)

0.948

2+

238 (26.3)

20 (24.7)

 

3+

287 (31.7)

28 (34.6)

 

GeneXpert

251 (27.7)

21 (25.9)

 

Drug regimen

2RHZE/4RH

560 (61.8)

41 (50.6)

0.136

2RHZE/6HE

280 (30.9)

33 (40.7)

 

2RHZES/1RHZE/5RHE

66 (7.3)

7 (8.6)

 

HIV status

Negative

673 (74.3)

31 (38.3)

< 0.001

Positive

233 (27.7)

50 (61.7)

 

Type of Directly Observed Therapy Short Course

Health facility

36 (4.0)

9 (11.1)

0.008

Community

870 (96.0)

72 (88.9)

 

Treatment support availability

No

111 (12.3)

11 (13.6)

0.864

Yes

795 (87.7)

70 (86.4)

 
  1. Note: 1) 2RHZE/4RH: 2 months of Rifampicin (R), Isoniazid (H), Pyrazinamide (Z),Ethambutol / 4 months of RH; 2) 2RHZE/6EH: 2 months of RHZE)/ 6 months of EH; 3) 2RHZES/IRHZE/5RHE: 2 months of RHZE, Streptomycin/One month of RHZE/ 5 months of RHE; 4) MTB: Mycobacterium tuberculosis